Tue, May 11, 2010
Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ] - Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ] - Market Wire
Quit the Board
Wed, December 30, 2009
Tue, December 29, 2009
Mon, December 28, 2009
Thu, December 24, 2009
Wed, December 23, 2009
Tue, December 22, 2009

Halozyme to Present at J.P. Morgan Healthcare Conference on January 13


//health-fitness.news-articles.net/content/2010/ .. -morgan-healthcare-conference-on-january-13.html
Published in Health and Fitness on Wednesday, January 6th 2010 at 21:00 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the [ extracellular matrix ], today announced its participation in the 28th Annual J.P. Morgan Healthcare Conference to be held on January 11-14, 2010 in San Francisco. Jonathan Lim, M.D., president and CEO, will present an overview of Halozyme and its product development [ pipeline ] on Wednesday, January 13, 2010 at 11:30 a.m. PST (2:30 p.m. EST).

To listen to the audio webcast of the presentation live or after the event, please visit the company's Web site at [ www.halozyme.com ]. The replay will be available for 90 days after the presentation.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze technology to Baxter's biological therapeutic compound, GAMMAGARD Liquid®. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit [ www.halozyme.com ].


Publication Contributing Sources